Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With CELLECTRA-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18.

NCT01304524 is registered in ClinicalTrials.gov with Inovio Pharmaceuticals as lead sponsor.

NCT NCT01304524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01304524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Placebo Controlled Study of VGX-3100, (HPV16 E6/E7, HPV18 E6/E7 DNA Vaccine) Delivered IM Followed by Electroporation With CELLECTRA-5P for the Treatment of Biopsy-proven CIN 2/3 or CIN 3 With Documented HPV 16 or 18.
Lead sponsor
Inovio Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2011
Completion date
April 30, 2015
Enrollment
167 (actual)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

cervical intraepithelial neoplasia